Unscripted: Exploring the Potential of GLP-1 Therapies

Guests:
Sebastian Seiguer, CEO, Scene Health
Michael Blaha, MD, MPH, Professor of Cardiology and Epidemiology, Director of the Cardiometabolic Clinic

Top Five Takeaways from the Panel

1. GLP-1s show transformative benefits beyond weight loss
Dr. Blaha explained that GLP-1 receptor agonists not only support weight reduction but also improve blood sugar control, lower cardiovascular risk, and may have protective effects on kidney health.

2. Access and affordability remain key barriers
Despite proven benefits, high costs and insurance hurdles continue to limit widespread adoption. Strategies for improving access are critical for long-term impact.

3. Adherence determines real-world outcomes
As Sebastian Seiguer noted, even the most effective medication cannot help if patients don’t take it consistently. Behavioral support and accountability tools are essential for persistence.

4. Digital health extends provider reach
Programs like Scene Health offer daily touchpoints that complement clinical care—helping members maintain motivation and overcome side effects or dosing challenges between appointments.

5. Partnerships can unlock population health gains
Collaboration between health systems, payers, and digital platforms can scale GLP-1 use responsibly, ensuring that evidence-based strategies translate into real health improvements.

Conclusion
The panel underscored that GLP-1 therapies represent a powerful new chapter in cardiometabolic care. But to maximize their potential, patients need support systems that address affordability, adherence, and daily habit-building—areas where digital health and human connection play a vital role.